2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 19 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neoplasm cells from patients with chronic myeloid leukemia (CML) interact with stromal cells of the surrounding microenvironment." | 1.46 | Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia. ( Fang, Q; Huang, J; Liu, P; Ma, D; Ren, M; Wang, J; Wang, P; Yu, M; Yu, Z; Zhe, N, 2017) |
| "Chronic myelogenous leukemia is characterized by the reciprocal chromosomal translocation (9;22), which generates a novel fusion gene, BCR-ABL." | 1.35 | HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells. ( Hirano, I; Nakamura, S; Ohnishi, K; Okinaka, K; Ono, T; Shigeno, K; Shinjo, K; Sugimoto, Y, 2008) |
| "The growth of maturing chronic myeloid leukemia cells is independent of BCR-ABL in the presence of growth factors." | 1.31 | The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. ( Aulitzky, WE; Duyster, J; Götz, A; Hallek, M; Jonuleit, T; Michels, H; Oetzel, C; van der Kuip, H, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, P | 1 |
| Ma, D | 1 |
| Yu, Z | 1 |
| Zhe, N | 1 |
| Ren, M | 1 |
| Wang, P | 1 |
| Yu, M | 1 |
| Huang, J | 1 |
| Fang, Q | 1 |
| Wang, J | 1 |
| Borges, CS | 1 |
| Ferreira, AF | 1 |
| Almeida, VH | 1 |
| Gomes, FG | 1 |
| Berzoti-Coelho, MG | 1 |
| Cacemiro, MDC | 1 |
| Nunes, NS | 1 |
| Figueiredo-Pontes, LL | 1 |
| Simões, BP | 1 |
| Castro, FA | 1 |
| Monteiro, RQ | 1 |
| Ciarcia, R | 1 |
| Damiano, S | 1 |
| Montagnaro, S | 1 |
| Pagnini, U | 1 |
| Ruocco, A | 1 |
| Caparrotti, G | 1 |
| d'Angelo, D | 1 |
| Boffo, S | 1 |
| Morales, F | 1 |
| Rizzolio, F | 1 |
| Florio, S | 1 |
| Giordano, A | 1 |
| Huang, FF | 1 |
| Zhang, L | 1 |
| Wu, DS | 1 |
| Yuan, XY | 1 |
| Yu, YH | 1 |
| Zhao, XL | 1 |
| Chen, FP | 1 |
| Zeng, H | 1 |
| Cheng, YL | 1 |
| Huang, WC | 1 |
| Chen, CL | 1 |
| Tsai, CC | 1 |
| Wang, CY | 1 |
| Chiu, WH | 1 |
| Chen, YL | 1 |
| Lin, YS | 1 |
| Chang, CF | 1 |
| Lin, CF | 1 |
| Yang, KT | 1 |
| Wang, MC | 1 |
| Chen, JY | 1 |
| Hsu, MC | 1 |
| Hung, WC | 1 |
| Kumano, K | 1 |
| Arai, S | 1 |
| Hosoi, M | 1 |
| Taoka, K | 1 |
| Takayama, N | 1 |
| Otsu, M | 1 |
| Nagae, G | 1 |
| Ueda, K | 1 |
| Nakazaki, K | 1 |
| Kamikubo, Y | 1 |
| Eto, K | 1 |
| Aburatani, H | 1 |
| Nakauchi, H | 1 |
| Kurokawa, M | 1 |
| Klejman, A | 1 |
| Rushen, L | 1 |
| Morrione, A | 1 |
| Slupianek, A | 1 |
| Skorski, T | 1 |
| Rahmani, M | 1 |
| Yu, C | 1 |
| Reese, E | 1 |
| Ahmed, W | 1 |
| Hirsch, K | 1 |
| Dent, P | 1 |
| Grant, S | 1 |
| Kubota, Y | 1 |
| Tanaka, T | 1 |
| Ohnishi, H | 1 |
| Kitanaka, A | 1 |
| Okutani, Y | 1 |
| Taminato, T | 1 |
| Ishida, T | 1 |
| Kamano, H | 1 |
| Marley, SB | 1 |
| Lewis, JL | 1 |
| Schneider, H | 1 |
| Rudd, CE | 1 |
| Gordon, MY | 1 |
| Jørgensen, HG | 1 |
| Allan, EK | 1 |
| Graham, SM | 1 |
| Godden, JL | 1 |
| Richmond, L | 1 |
| Elliott, MA | 1 |
| Mountford, JC | 1 |
| Eaves, CJ | 1 |
| Holyoake, TL | 1 |
| Hickey, FB | 1 |
| Cotter, TG | 1 |
| Jin, L | 1 |
| Kato, A | 1 |
| Tabe, Y | 1 |
| Svensson, E | 1 |
| Vidovic, K | 1 |
| Lassen, C | 1 |
| Richter, J | 1 |
| Olofsson, T | 1 |
| Fioretos, T | 1 |
| Gullberg, U | 1 |
| Sugimoto, Y | 1 |
| Nakamura, S | 1 |
| Okinaka, K | 1 |
| Hirano, I | 1 |
| Ono, T | 1 |
| Shigeno, K | 1 |
| Shinjo, K | 1 |
| Ohnishi, K | 1 |
| Oetzel, C | 1 |
| Jonuleit, T | 2 |
| Götz, A | 1 |
| van der Kuip, H | 2 |
| Michels, H | 2 |
| Duyster, J | 2 |
| Hallek, M | 2 |
| Aulitzky, WE | 2 |
| Miething, C | 1 |
| Bhatia, R | 1 |
| Munthe, HA | 1 |
| Forman, SJ | 1 |
19 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Cellular Microenvironment; | 2017 |
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Chromones; Di | 2018 |
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
Topics: Apoptosis; Autophagy; Benzamides; Calcium; Calcium Signaling; Cell Line, Tumor; Chromones; Drug Syne | 2013 |
PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia.
Topics: Adult; Aged; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassett | 2014 |
Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli.
Topics: Apoptosis; bcl-X Protein; Cell Line, Tumor; Cell Survival; Chromones; Drug Resistance, Neoplasm; Gal | 2011 |
Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of β-catenin and STAT1 in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzamides; beta | 2011 |
Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples.
Topics: Animals; Butadienes; Cell Differentiation; Cells, Cultured; Chromones; Cluster Analysis; Coculture T | 2012 |
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Topics: Androstadienes; Antineoplastic Agents; Benzamides; Caspase 3; Caspases; Chromones; Drug Synergism; E | 2002 |
Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition.
Topics: Apoptosis; Benzamides; Butyrates; Chromones; Complement Membrane Attack Complex; Complement System P | 2003 |
Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation.
Topics: Androstadienes; Blood Platelets; Chromones; Dose-Response Relationship, Drug; Enzyme Activation; Enz | 2004 |
Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells.
Topics: Alkyl and Aryl Transferases; Androstadienes; Antineoplastic Agents; Benzamides; Blotting, Western; C | 2004 |
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Line | 2005 |
Identification of transcriptional targets associated with the expression of p210 Bcr-Abl.
Topics: Animals; Benzamides; Cell Line; Cell Proliferation; Cells, Cultured; Chromones; Class I Phosphatidyl | 2006 |
[The anti-tumoral effect of PI3K inhibitor and MEK inhibitor combined with STI571 on chronic myeloid leukemia cells in a bone marrow stromal cell co-culture system].
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Cell Proliferation; Chromones; Cocu | 2006 |
Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cells, Cultured; Chromones; Drug Resistance, Neoplasm; Etop | 2007 |
HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Topics: Adult; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Case-Control Studies; Cell Cycle; Cell | 2008 |
The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Topics: Animals; Apoptosis; bcl-X Protein; Benzamides; Caspase 3; Caspases; Cell Count; Cell Division; Chrom | 2000 |
Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.
Topics: Animals; Blotting, Western; Cell Cycle Proteins; Cell Division; Cell Line; Chromones; Culture Media; | 2000 |
Abnormal growth factor modulation of beta1-integrin-mediated adhesion in chronic myelogenous leukaemia haematopoietic progenitors.
Topics: Androstadienes; Case-Control Studies; Cell Adhesion; Cell Cycle Proteins; Cell Movement; Cells, Cult | 2001 |